| Product Name | Anti-HLA DRA Antibody [IPO-10] |
|---|---|
| Description | Mouse monoclonal [IPO-10] antibody to HLA DRA. |
| Host | Mouse |
| Clonality | Monoclonal |
| Clone | IPO-10 |
| Conjugate | Unconjugated |
| Immunogen | Spleen cells of a patient with hairy cell leukemia (Daudi cells). |
| Isotype | IgG3 |
| Molecular Weight | ~36 kDa |
| Target | HLA DRA |
| Specificity | This antibody defines the antigen, which appears on B cell progenitors following HLA-DR and preceding CD10, CD19, CD22, CD37, and cym. It is expressed on resting B cells and than reappears and persists in cytoplasm and on cell surface until cytoplasmic Ig appears. It is a useful antibody for diagnosis of neoplasms of B cell origins. It reacts with human B cell lines Daudi, Raji, Namalva, EB-3, and RPMI-8226 (50% of cells). This antibody does not label T cell lines, blood granulocytes, thymocytes, or bone marrow stromal fibroblasts. No significant changes are detected after PHA or ConA stimulation while LPS and PWM stimulated cultures after 18-48h show decreased number of antigen-positive cells but in final terms of cultivation antigen is expressed again. This antibody labels B cell leukemias and some lymphomas. Hairy cell leukemia strongly reacts and 70% of B cell CLL and some B-NHL were also positive. This antibody reacts with AMML cells and in a majority of Hodgkins disease cases a significant percentage of affected lymph node cells were detected. |
| Reactivity | Monkey, Human |
| Applications | FC, IF |
| Working Dilutions | Flow Cytometry: 1-2 µg/million cells, IF: 1-2 µg/ml |
| Form | Liquid |
| Diluent Buffer | Supplied in 10mM Phosphate Buffered Saline with 0.05% BSA and 0.05% Sodium Azide. |
| Concentration | 200 µg/ml |
| Storage | Shipped at 4°C. Store at 4°C. |
| Supplier | Antibodies.com |
All Research Products are sold for laboratory RESEARCH USE ONLY and ARE NOT TO BE USED FOR HUMAN OR ANIMAL THERAPEUTIC OR DIAGNOSTIC APPLICATIONS. The information presented is believed to be accurate; however, said information and products are offered without warranty or guarantee since the ultimate conditions of use and the variability of the materials treated are beyond our control. Nothing disclosed herein is to be construed as a recommendation to use our products in violation of any patents. ARP American Research Products, Inc. does not submit its products for regulatory review by any government body or other organization, and we do not validate them for clinical, therapeutic or diagnostic use, or for safety and effectiveness. You are solely responsible for making sure that the way you use the products complies with applicable laws, regulations and governmental policies and for obtaining all necessary approvals, intellectual property rights, licenses and permissions that you may need related to your use. Under no circumstances shall ARP American Research Products, Inc. be liable for damages, whether consequential, compensatory, incidental or special, strict liability or negligence, breach of warranty or any other theory arising out of the use of the products available from ARP American Research Products, Inc. Nothing contained herein warrants that the use of the products will not infringe on the claims of any patents covering the product itself or the use thereof in combination with other products or in the operation of any process. ARP American Research Products, Inc. disclaims any and all representations or warranties of any kind whatsoever, express or implied, including without limitation any implied warranties of merchantability or fitness for a particular purpose, of non-infringement, or regarding results obtained through the use of any product, whether arising from a statute or otherwise in law or from a course of performance, dealing or usage of trade.
